Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
13.97
-0.38 (-2.68%)
Mar 28, 2024, 3:32 PM EDT - Market open

Entrada Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Cash & Equivalents
71.5549.11291.0639.0516.84
Short-Term Investments
284.37143.56000
Cash & Cash Equivalents
355.92192.66291.0639.0516.84
Cash Growth
84.74%-33.81%645.46%131.80%-
Receivables
5.880000
Other Current Assets
7.9717.217.640.90.59
Total Current Assets
369.77209.88298.739.9517.44
Property, Plant & Equipment
92.6833.026.263.040.8
Other Long-Term Assets
6.749.160.870.540
Total Long-Term Assets
99.4242.187.133.580.8
Total Assets
469.19252.06305.8343.5318.24
Accounts Payable
3.285.990.711.60.71
Deferred Revenue
139.980000
Current Debt
7.918.41000
Other Current Liabilities
7.637.586.011.761.21
Total Current Liabilities
158.821.976.723.361.92
Long-Term Debt
60.3217.53000
Other Long-Term Liabilities
7.7200.400.02
Total Long-Term Liabilities
68.0417.530.400.02
Total Liabilities
226.8339.57.123.361.94
Total Debt
68.2325.94000
Debt Growth
163.07%----
Retained Earnings
-194.97-188.29-93.67-42.51-15.99
Comprehensive Income
0.2-2.06000
Shareholders' Equity
242.36212.55298.72-41.49-15.52
Net Cash / Debt
287.69166.73291.0639.0516.84
Net Cash / Debt Growth
72.55%-42.72%645.46%131.80%-
Net Cash Per Share
8.705.3346.4435.332.49
Working Capital
210.98187.9291.9836.5915.52
Book Value Per Share
7.336.7947.66-37.54-2.30
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).